• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo.结核分枝杆菌对利奈唑胺和地拉曼尼的耐药性：来自刚果民主共和国布卡武的一例报告。
BMC Infect Dis. 2025 Jul 12;25(1):913. doi: 10.1186/s12879-025-11348-w.
2
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.评估无培养靶向新一代测序技术在诊断耐多药结核病中的应用：两种端到端商业工作流程的多中心临床研究
Lancet Infect Dis. 2025 Mar;25(3):325-334. doi: 10.1016/S1473-3099(24)00586-3. Epub 2024 Oct 29.
3
Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.工程化分枝杆菌噬菌体TM4::GeNL可快速测定结核分枝杆菌临床分离株对贝达喹啉、普瑞玛尼、利奈唑胺、利福平及氯法齐明的敏感性。
J Infect Dis. 2025 Apr 15;231(4):859-870. doi: 10.1093/infdis/jiae438.
4
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.韩国耐多药和广泛耐药结核病中德拉马尼、贝达喹啉和利奈唑胺最低抑菌浓度分布及耐药相关基因突变。
Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563.
5
Mutations associated with resistance to rifampicin and isoniazid identified in strains of the complex by GenoType MTBDRplus in Panama, 2015-2021.2015年至2021年在巴拿马通过GenoType MTBDRplus在该复合体菌株中鉴定出的与利福平及异烟肼耐药相关的突变。
Microbiol Spectr. 2025 Jul;13(7):e0240024. doi: 10.1128/spectrum.02400-24. Epub 2025 Jun 9.
6
A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection of and drug resistance.一项使用Xpert MTB/RIF和培养方法的对比研究评估了MassARRAY技术用于快速检测及耐药性检测的情况。
Front Cell Infect Microbiol. 2025 Jul 9;15:1539240. doi: 10.3389/fcimb.2025.1539240. eCollection 2025.
7
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.德拉马尼与贝达喹啉联合用于治疗耐多药和广泛耐药结核病：一项系统评价
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
8
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.Xpert MTB/XDR 检测系统用于检测肺结核病及异烟肼、氟喹诺酮类、乙胺丁醇和阿米卡星耐药性。
Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2.
9
Delayed culture conversion predicts poor outcomes for isoniazid mono-resistant TB in Uganda: a retrospective cross-sectional study from 2017- 2022.延迟培养转阴预示乌干达异烟肼单耐药结核病的不良结局：一项2017 - 2022年的回顾性横断面研究
BMC Infect Dis. 2025 Jul 1;25(1):821. doi: 10.1186/s12879-025-11218-5.
10
Drug resistance profile of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients and their household contacts in central Ethiopia.从埃塞俄比亚中部肺结核患者及其家庭接触者中分离出的结核分枝杆菌复合群的耐药谱
BMC Infect Dis. 2025 Jun 20;25(1):806. doi: 10.1186/s12879-025-11220-x.

本文引用的文献

1
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda.利福平耐药性Xpert MTB/RIF检测结果假阳性的患病率及驱动因素：卢旺达的一项前瞻性观察研究
Lancet Microbe. 2020 Jun;1(2):e74-e83. doi: 10.1016/S2666-5247(20)30007-0. Epub 2020 Jun 8.
2
Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests.基于薄层琼脂的斯威士兰痰直接药敏试验快速检测结核分枝杆菌生长和利福平耐药，而世界卫生组织推荐的诊断检测方法可能会漏检。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02263-20.
3
Delamanid Resistance: Update and Clinical Management.德拉马尼耐药性：更新与临床管理。
Clin Infect Dis. 2020 Dec 15;71(12):3252-3259. doi: 10.1093/cid/ciaa755.
4
Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs.整合信息学工具和便携式测序技术，用于快速检测抗结核药物耐药性。
Genome Med. 2019 Jun 24;11(1):41. doi: 10.1186/s13073-019-0650-x.
5
Discordant rifampicin susceptibility results are associated with Xpert MTB/RIF probe B and probe binding delay.利福平耐药性检测结果不一致与 Xpert MTB/RIF 探针 B 和探针结合延迟有关。
Int J Tuberc Lung Dis. 2019 Mar 1;23(3):358-362. doi: 10.5588/ijtld.16.0837.
6
Comparison of Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.比较新型恶唑烷酮类药物 delpazolid 与利奈唑胺对中国耐多药和广泛耐药结核分枝杆菌的活性和 MIC 分布。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00165-18. Print 2018 Aug.
7
Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.结核分枝杆菌的异烟肼耐药水平很大程度上可以通过高可信度耐药相关突变来预测。
Sci Rep. 2018 Feb 19;8(1):3246. doi: 10.1038/s41598-018-21378-x.
8
Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.结核分枝杆菌耐药性的演变：耐药分子决定因素及其对个体化治疗的影响综述。
J Antimicrob Chemother. 2018 May 1;73(5):1138-1151. doi: 10.1093/jac/dkx506.
9
Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis.撒哈拉以南非洲地区耐多药结核病流行趋势：系统评价与荟萃分析
PLoS One. 2017 Sep 25;12(9):e0185105. doi: 10.1371/journal.pone.0185105. eCollection 2017.
10
Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.异恶唑烷酮类耐药结核分枝杆菌的分离与鉴定。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01296-17. Print 2017 Oct.

结核分枝杆菌对利奈唑胺和地拉曼尼的耐药性：来自刚果民主共和国布卡武的一例报告。

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo.

作者信息

Bisimwa Bertin C, Bahizire Esto, Kiselinova Maja, Byela Valéry, Ngabonziza Jean Claude S, Hakizayezu François, Runyambo Docteur, Meehan Conor J, Mulders Wim, Cuella-Martin Isabel, Rigouts Leen, Birembano Freddy, Callens Steven, de Jong Bouke C, Kaswa Michel

机构信息

Center for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, South Kivu, Congo.

Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

出版信息

BMC Infect Dis. 2025 Jul 12;25(1):913. doi: 10.1186/s12879-025-11348-w.

DOI:10.1186/s12879-025-11348-w
PMID:40652177
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12255050/
Abstract

The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.

摘要

耐药性的出现是结核病控制中极为令人担忧的问题，尤其是对治疗利福平耐药所需的新型和重新利用的药物而言。我们报告了一名来自刚果民主共和国东部南基伍省的患者，其对地拉马尼和利奈唑胺存在原发性耐药，且此前未使用过这些药物进行治疗。新型耐药突变的发现引发了对世界卫生组织推荐的口服治疗方案可能在全球传播以及治疗效果不佳的担忧，凸显了迫切需要推广开展药敏试验的必要性。